Common Variable Immunodeficiency clinical trials at University of California Health
1 research study open to eligible people
Showing trials for
Abatacept for the Treatment of Common Variable Immunodeficiency With Interstitial Lung Disease
open to eligible people ages 4 years and up
There is no standard of care therapy for patients with granulomatous-lymphocytic interstitial lung disease (GLILD) seen in common variable immunodeficiency (CVID). Abatacept has recently looked promising for the treatment of patients with complex CVID. This study is a multi-site, phase II, randomized, blinded/placebo-controlled clinical trial in pediatric and adult subjects to determine the efficacy of abatacept compared to placebo for treatment of subjects with GLILD in the context of CVID. Funding Source - FDA OOPD
Our lead scientists for Common Variable Immunodeficiency research studies include Michele Pham, MD.